转移性肾细胞癌的靶向治疗

doi:10.3760/cma.j.issn.1673-422X.2014.09.010

摘要/Abstract

摘要： 抗血管生成治疗是转移性肾细胞癌的标准治疗。近年来，肿瘤新生血管通路的众多抑制剂纷纷进入临床研究，部分靶向药物取得良好的临床疗效。其他信号通路阻断剂如哺乳动物雷帕霉素靶蛋白与成纤维生长因子受体通路抑制剂也取得一定的成果。

Abstract: Targeted therapy of antiangiogensis strategy is the standard treatment for metastatic renal cell cancer. In recent years, a number of new generation of antiangiogensis agents have been tested in clinical trials, some of which have achieved promising outcomes. Other pathway inhibitors such as inhibitors of mammalian target of rapamycin and fibroblast growth factor receptor pathway have made progresses in some extent.

Key words: Kidney neoplasms, Molecular targeted therapy, Vascular endothelial growth factor A

王鸿彪,李绪渊,林文照. 转移性肾细胞癌的靶向治疗[J]. 国际肿瘤学杂志, 2014, 41(8): 672-674.

Wang Hongbiao, Li Xuyuan, Lin Wenzhao. Targeted therapy of metastatic renal cell cancer[J]. Journal of International Oncology, 2014, 41(8): 672-674.

参考文献

［1］ Iacovelli R, Alesini D, Palazzo A, et al. Targeted therapies and complete responses in first line treatment of metastatic renal cell carcinoma. A metaanalysis of published trials［J］. Cancer Treat Rev, 2014, 40(2): 271-275. ［2］ Pal SK, Quinn DI. Differentiating mTOR inhibitors in renal cell carcinoma［J］. Cancer Treat Rev, 2013, 39(7): 709-719. ［3］ Négrier S, Gravis G, Pérol D, et al. Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial［J］. Lancet Oncol, 2011, 12(7): 673-680. ［4］ Rini BI, Bellmunt J, Clancy J, et al. Randomized phase Ⅲ trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial［J］. J Clin Oncol, 2014, 32(8): 752-759. ［5］ Hutson TE, Lesovoy V, AlShukri S, et al. Axitinib versus sorafenib as firstline therapy in patients with metastatic renalcell carcinoma: a randomised openlabel phase 3 trial［J］. Lancet Oncol, 2013, 14(13): 1287-1294. ［6］ Motzer RJ, Nosov D, Eisen T, et al. Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase Ⅲ trial［J］. J Clin Oncol, 2013, 31(30): 3791-3799. ［7］ Sternberg CN, Hawkins RE, Wagstaff J, et al. A randomised, doubleblind phase Ⅲ study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update［J］. Eur J Cancer, 2013, 49(6): 1287-1296. ［8］ Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus sunitinib in metastatic renalcell carcinoma［J］. N Engl J Med, 2013, 369(8): 722-731. ［9］ Eisen T, Joensuu H, Nathan PD, et al. Regorafenib for patients with previously untreated metastatic or unresectable renalcell carcinoma: a singlegroup phase 2 trial［J］. Lancet Oncol, 2012, 13(10): 1055-1062. ［10］ Mulders P, Hawkins R, Nathan P, et al. Cediranib monotherapy in patients with advanced renal cell carcinoma: results of a randomised phase Ⅱ study［J］. Eur J Cancer, 2012, 48(4): 527-537. ［11］ Hutson TE, Escudier B, Esteban E, et al. Randomized phase Ⅲ trial of temsirolimus versus sorafenib as secondline therapy after sunitinib in patients with metastatic renal cell carcinoma［J］. J Clin Oncol, 2014, 32(8): 760-767. ［12］ Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial［J］. Lancet, 2011, 378(9807): 1931-1939. ［13］ Motzer RJ, Escudier B, Tomczak P, et al. Axitinib versus sorafenib as secondline treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial［J］. Lancet Oncol, 2013, 14(6): 552-562. ［14］ Fishman MN, Srinivas S, Hauke RJ, et al. Phase Ⅰb study of tivozanib (AV951) in combination with temsirolimus in patients with renal cell carcinoma［J］. Eur J Cancer, 2013, 49(13): 2841-2850. ［15］ Motzer R, Porta C, Vogelzang NJ, et al. Dovitinib versus sorafenib for thirdline targeted treatment of patients with metastatic renal cell carcinoma: an openlabel, randomised phase 3 trial［J］. Lancet Oncol, 2014, 15(3): 286-296.

[1]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[2]	王培鑫, 赵军, 徐世红, 姜朝阳, 王小强, 杨红娟. 铁死亡相关机制在骨肉瘤中的应用进展[J]. 国际肿瘤学杂志, 2024, 51(5): 308-311.
[3]	杨智, 陆以乔, 顾花艳, 丁佳玲, 郭贵龙. 肿瘤微环境介导乳腺癌靶向治疗耐药的研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 235-238.
[4]	张栋岩, 王品, 魏秋亚, 邓成伍, 魏相相, 高远飞, 王琛. 索凡替尼靶向联合卡培他滨和奥沙利铂治疗肝内胆管癌术后患者1例及文献复习[J]. 国际肿瘤学杂志, 2024, 51(4): 249-253.
[5]	马正红, 姜超. 非小细胞肺癌KRAS^G12C突变的研究进展[J]. 国际肿瘤学杂志, 2024, 51(2): 95-98.
[6]	黄辉, 丁江华. 靶向FGFR2治疗晚期胆管癌的研究进展[J]. 国际肿瘤学杂志, 2023, 50(9): 569-573.
[7]	李开春, 丁昌利, 于文艳. 安罗替尼联合特瑞普利单抗治疗晚期肺肉瘤样癌1例[J]. 国际肿瘤学杂志, 2023, 50(8): 511-512.
[8]	陈秋, 王雷, 王明琦, 张梅. 恩沃利单抗联合阿昔替尼治疗肾癌肺转移1例并文献复习[J]. 国际肿瘤学杂志, 2023, 50(7): 445-448.
[9]	李青珊, 谢鑫, 张楠, 刘帅. 放疗联合系统治疗在乳腺癌中的应用进展[J]. 国际肿瘤学杂志, 2023, 50(6): 362-367.
[10]	刘利, 朱思齐, 孙梦颖, 何敬东. PARP抑制剂在小细胞肺癌靶向治疗中的进展[J]. 国际肿瘤学杂志, 2023, 50(6): 368-372.
[11]	刘博翰, 黄俊星. 溶质载体SLC7A5及SLC7A11基因在恶性肿瘤中的研究进展[J]. 国际肿瘤学杂志, 2023, 50(5): 280-284.
[12]	朱军, 黄美金, 李媛, 刘泽刚, 荀欣, 陈宏. HER2低表达乳腺癌的靶向治疗研究进展[J]. 国际肿瘤学杂志, 2023, 50(4): 236-240.
[13]	邓莉莉, 段星宇, 李保中. HER2靶向药物及其联合治疗方案在胃及食管胃结合部腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2023, 50(12): 751-757.
[14]	刘绍平, 罗汉传, 林书瀚, 罗家辉. 中晚期肝细胞癌介入及系统治疗的现状与研究进展[J]. 国际肿瘤学杂志, 2023, 50(12): 758-762.
[15]	江山, 徐细明. 肝细胞癌的靶向及免疫治疗新进展[J]. 国际肿瘤学杂志, 2023, 50(11): 688-695.